Leucovorin
- Generic Name
- Leucovorin
- Brand Names
- EnBrace HR, EnLyte, Lederle Leucovorin
- Drug Type
- Small Molecule
- Chemical Formula
- C20H23N7O7
- CAS Number
- 58-05-9
- Unique Ingredient Identifier
- Q573I9DVLP
- Background
Folinic Acid (also known as 5-formyl tetrahydrofolic acid or leucovorin) is the 5-formyl derivative of tetrahydrofolic acid, a necessary co-factor in the body. Commercially available leucovorin is composed of a 1:1 racemic mixture of the dextrorotary and levorotary isomers, while levoleucovorin contains only the pharmacologically active levo-isomer. In vitro...
- Indication
For the treatment of osteosarcoma (after high dose methotrexate therapy). Used to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists, and to treat megaloblastic anemias due to folic acid deficiency. Also used in combination with 5-fluorouracil to prolong survival in t...
- Associated Conditions
- Advanced Colorectal Cancer, Advanced Esophageal Cancers, Anemia of Pregnancy, Bladder Cancer, Folate and iron deficiency, Folate deficiency, Folic acid antagonist overdose, Iron Deficiency (ID), Macrocytic anemia, Megaloblastic anemia, Pancreatic Metastatic Cancer, Postpartum Anemia, Stage IV Gastric Cancer, Hypochromic anemia, Methotrexate toxicity, Normochromic anemia, Pyrimethamine hematologic toxicity
- Associated Therapies
- -
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
- First Posted Date
- 2006-06-16
- Last Posted Date
- 2007-11-19
- Lead Sponsor
- Mast Therapeutics, Inc.
- Target Recruit Count
- 1200
- Registration Number
- NCT00337389
- Locations
- đşđ¸
Research Site In, San Diego, California, United States
Research Center In, Zrenjanin, Former Serbia and Montenegro
đşđ¸Mercy General Hospital, Sacramento, California, United States
Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 26
- Registration Number
- NCT00335140
- Locations
- đşđ¸
West Michigan Cancer Center, Kalamazoo, Michigan, United States
đşđ¸Minnesota Oncology Hematology, PA - Woodbury, Woodbury, Minnesota, United States
đşđ¸Bronson Methodist Hospital, Kalamazoo, Michigan, United States
Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2007-05-08
- Lead Sponsor
- Seattle Cancer Treatment and Wellness Center
- Target Recruit Count
- 80
- Registration Number
- NCT00323583
- Locations
- đşđ¸
Seattle Cancer Treatment and Wellness Center, Seattle, Washington, United States
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 90
- Registration Number
- NCT00321828
- Locations
- đşđ¸
Kaiser Permanente Medical Center - Redwood City, Redwood City, California, United States
đşđ¸Meeker County Memorial Hospital, Litchfield, Minnesota, United States
đşđ¸Great Falls Clinic - Main Facility, Great Falls, Montana, United States
Randomized Study on Neoadjuvant Radio-Chemotherapy in Rectal Carcinoma Dukes B and C
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2006-04-03
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 700
- Registration Number
- NCT00309517
- Locations
- đŚđš
Hospital Baden, Baden bei Wien, Lower Austria, Austria
đŚđšHospital Hainburg, Hainburg, Lower Austria, Austria
đŚđšHospital Oberpullendorf, Oberpullendorf, Burgenland, Austria
Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2006-04-03
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 636
- Registration Number
- NCT00309543
- Locations
- đŚđš
Hospital Hainburg, Hainburg, Lower Austria, Austria
đŚđšHospital Oberpullendorf, Oberpullendorf, Burgenland, Austria
đŚđšMedical University Vienna, General Hospital, Vienna, Austria
5-Fluorouracil, Bevacizumab, and Radiation Followed by Modified FOLFOX6 and Bevacizumab in Stage II/III Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 66
- Registration Number
- NCT00308516
- Locations
- đşđ¸
Florida Cancer Specialists, Fort Myers, Florida, United States
đşđ¸Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
đşđ¸Northeast Alabama Regional Medical Center, Anniston, Alabama, United States
Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.
- Conditions
- Interventions
- First Posted Date
- 2006-03-21
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 879
- Registration Number
- NCT00305188
- Locations
- đŹđ§
Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom
Effect of Specific Anti-Toxoplasmatic Add-on Medication in Toxoplasma Gondii Seropositive Individuals With Schizophrenia or Major Depression
- Conditions
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2006-05-22
- Lead Sponsor
- Zentrum fĂźr Integrative Psychiatrie
- Target Recruit Count
- 40
- Registration Number
- NCT00300404
Efficacy Study of Folinic Acid to Improve Mental Development of Children With Down Syndrome
- Conditions
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2009-12-17
- Lead Sponsor
- Institut Jerome Lejeune
- Target Recruit Count
- 120
- Registration Number
- NCT00294593
- Locations
- đŤđˇ
Institut Jerome Lejeune, Paris, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.